Drug Trial Radar · NCT01161927
Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions
Last checked: Nov 20, 2026Latest source record: Jul 14, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Jul 2004
Primary completion
Sep 2004
Study completion Sep 2004
Sponsor
- Lead sponsor
- Dr. Reddy's Laboratories Limited, IndiaIndustry
- Sponsor type
- Industry
- First posted
- Jul 14, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare experimental evaluation of relative bioavailabilities in healthy, human subjects under non-fasting conditions.
Conditions
- Healthy
Interventions
NizatidineDrug
Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
AxidDrug
Axid 300 mg Capsules of Reliant Pharmaceuticals, US
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bioequivalence based on Cmax and AUC parametersTime frame: 3 Months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.